Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-10-17
DOI
https://doi.org/10.1200/jco.24.00321
Citations
25
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
7.06
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

Jozal Moore, Lori S. Muffly, Melhem Solh, Rawan Faramand et al.
25 citations
Journal of Clinical Oncology
CAR-T cell therapy research
7.06
article

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

Jozal Moore, Lori S. Muffly, Melhem Solh, Rawan Faramand, Danielle Bradshaw, Wendy Stock, Joshua Sasine, Catherine J. Lee, Simone E. Dekker, George Yaghmour, Paul Shaughnessy, Michal Kubiak, Santiago Mercadal, Navneet S. Majhail, Divya Koura, Marlise Rachael Luskin, Matthew P. Connor, Vinod A. Pullarkat, Akash Mukherjee, Bijal Shah, Naveed Ahmed, Marc S. Schwartz, Luke Mountjoy, Caspian Oliai, Jessica Leonard, Vishal Gupta, Ibrahim Taha Aldoss, Gregory W. Roloff, Noam E. Kopmar, Muthu Veeraputhiran, Evan Chris Chen, Rasmus T. Hoeg, LaQuisa C. Hill, Bhagirathbhai Dholaria, Betsy Blunk, Kristen M. O'Dwyer, John Mathews, Ibrahim N. Muhsen, Vamsi Kota, Caitlin Guzowski, Veronika Bachanová, Sang‐Bing Tsai, Talal Hilal, Chenyu Lin, Aaron C. Logan, Ryan D. Cassaday, Minoo Battiwalla, Sean Tracy, Kaitlyn C. Dykes, Abdullah Ladha, Anjali S. Advani, Kate Miller, Yannis K. Valtis, Noelle V. Frey, Timothy E. O’Connor, Michael R. Bishop, Nikeshan Jeyakumar, Amy Zhang, Mohamed Ahmed, Jae H. Park, Ahmed Galal, Shahbaz A. Malik, Maryann Stefan, Héctor Zambrano, Katherine Sutherland
article en
25 citations

Abstract

Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.

Journal of Clinical OncologyVol. 43(5)
Northside Hospital (US), University of Southern California (US), Cedars-Sinai Medical Center (US), City Of Hope National Medical Center (US), University of Minnesota (US), Loyola University Medical Center (US), Memorial Sloan Kettering Cancer Center (US), University of California, Los Angeles (US), Oregon Health & Science University (US), Duke University (US), University of California, San Francisco (US), Baylor College of Medicine (US), University of Washington (US), University of Utah (US), University of Arkansas Medical Center (US), Huntsman Cancer Institute (US), University of Rochester Medical Center (US), Moffitt Cancer Center (US), University of California San Diego (US), University of Chicago (US), Augusta University Health (US), Sarah Cannon (US), Methodist Hospital (US), Dana-Farber Cancer Institute (US), Mayo Clinic Hospital (US), Stanford Blood Center (US), University of Colorado Anschutz Medical Campus (US), University of Pennsylvania (US), University of California, Davis (US), Vanderbilt University Medical Center (US), Stanford University (US)
Zero hunger
Openalex Percentile: Top 2%
CAR-T cell therapy research
7.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.